Omeros (NASDAQ:OMER) Director Arnold Hanish Sells 10,000 Shares

Omeros Corporation (NASDAQ:OMER) Director Arnold Hanish sold 10,000 shares of Omeros stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $18.95, for a total value of $189,500.00. Following the completion of the sale, the director directly owned 5,000 shares of the company’s stock, valued at approximately $94,750. This represents a 66.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Omeros Trading Down 3.3%

Omeros stock opened at $18.61 on Friday. The stock has a fifty day moving average price of $12.64 and a 200 day moving average price of $12.03. Omeros Corporation has a 52 week low of $3.94 and a 52 week high of $19.65. The firm has a market capitalization of $1.35 billion, a P/E ratio of 14.54 and a beta of 2.54.

Omeros (NASDAQ:OMER) last issued its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.29. The business had revenue of $28.53 million during the quarter, compared to analyst estimates of $12.69 million. As a group, equities analysts predict that Omeros Corporation will post -0.37 EPS for the current year.

Institutional Trading of Omeros

A number of institutional investors have recently modified their holdings of OMER. BlackRock Inc. acquired a new stake in Omeros during the 2nd quarter worth approximately $57,484,000. UBS Group AG lifted its position in Omeros by 213.5% during the fourth quarter. UBS Group AG now owns 2,222,982 shares of the biopharmaceutical company’s stock valued at $38,180,000 after buying an additional 1,513,893 shares in the last quarter. California State Teachers Retirement System grew its stake in Omeros by 19,094.9% during the second quarter. California State Teachers Retirement System now owns 720,192 shares of the biopharmaceutical company’s stock worth $75,730,000 after buying an additional 716,440 shares during the period. Vanguard Group Inc. grew its stake in Omeros by 19.9% during the fourth quarter. Vanguard Group Inc. now owns 4,013,315 shares of the biopharmaceutical company’s stock worth $68,929,000 after buying an additional 666,357 shares during the period. Finally, Corient Private Wealth LP purchased a new stake in Omeros during the second quarter worth approximately $6,274,000. Hedge funds and other institutional investors own 48.79% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. Zacks Research downgraded shares of Omeros from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th. HC Wainwright reiterated a “buy” rating on shares of Omeros in a report on Monday, July 27th. Wall Street Zen upgraded shares of Omeros from a “hold” rating to a “buy” rating in a report on Saturday, August 15th. Finally, Weiss Ratings raised shares of Omeros from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $38.00.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.